1/11/2024 | CV | Market Commentary: Federal Realty, Evergy active; TechTarget skyrockets; Cytokinetics plummets outright
|
1/9/2024 | CV | Market Commentary: Federal Realty exchangeable notes in focus, expand on debut; Cytokinetics trades lower
|
1/8/2024 | CV | Market Commentary: Federal Realty convertibles eyed; Spirit AeroSystems under pressure; Cytokinetics active
|
1/5/2024 | CV | Market Commentary: OPKO Health convertibles price, drop below par on debut; PG&E active; Cytokinetics gains
|
1/4/2024 | CV | Market Commentary: OPKO convertible offering eyed; refinancing wave begins; Cytokinetics rally continues
|
12/8/2022 | PV | Cytokinetics extends deadlines for conditions to draw tranche 2, 3 loans
|
7/26/2022 | CV | Market Commentary: Ormat convertible notes add to gains; Cytokinetics on the rise; Coinbase under pressure
|
7/20/2022 | CV | Market Commentary: Envestnet convertible notes active; Silicon jumps; equities have another good day
|
7/6/2022 | CV | Market Commentary: Pioneer Natural Resources convertibles in focus; Cytokinetics gains; Airbnb active
|
7/6/2022 | CV | Cytokinetics greenshoe ups 3.5% convertibles due 2027 to $540 million
|
7/6/2022 | CV | Market Commentary: Morning Commentary: Pioneer Resources convertibles in focus; Cytokinetics adds to gains
|
7/5/2022 | CV | Market Commentary: Cytokinetics convertibles rise; Booking notes active; JPMorgan, BofA synthetics trade
|
7/5/2022 | CV | Market Commentary: Morning Commentary: Cytokinetics convertibles add to gains; Booking notes active early
|
7/1/2022 | CV | Market Commentary: Cytokinetics convertibles price, skyrocket on debut; Etsy gains; BridgeBio hits new low
|
7/1/2022 | CV | Market Commentary: Morning Commentary: Cytokinetics convertibles hit the aftermarket, skyrocket on debut
|
7/1/2022 | CV | New Issue: Cytokinetics prices $450 million five-year convertible notes to yield 3.5%, up 30%
|
6/30/2022 | CV | Market Commentary: Aspen Aerogels convertibles offering pulled; Cytokinetics on tap; Upstart retests lows
|
6/30/2022 | CV | Market Commentary: Morning Commentary: Aspen Aerogels convertibles offering pulled; Cytokinetics on tap
|
6/29/2022 | CV | Cytokinetics talks $450 million five-year convertible notes to yield 3%-3.5%, up 30%-35%
|
6/29/2022 | CV | Market Commentary: Cytokinetics convertibles on tap; Aspen Aerogels cancels; Carnival, Royal Caribbean sink
|
10/8/2020 | CV | Market Commentary: Fiverr convertibles skyrocket on debut; Cytokinetics expands as stock tanks; ON active
|
10/8/2020 | CV | Market Commentary: Morning Commentary: Fiverr prices, skyrockets on debut; Cytokinetics active, stock tanks
|
7/10/2020 | CV | Market Commentary: Maxeon Solar upsizes convertibles; Palo Alto, Cytokinetics active; Health Catalyst gains
|
11/13/2019 | CV | Cytokinetics greenshoe ups 4% seven-year convertibles to $138 million
|
11/8/2019 | CV | Market Commentary: Stanley Black & Decker ‘trades well’; Cytokinetics drags outright; LivePerson adds on swap
|
11/8/2019 | CV | Market Commentary: Morning Commentary: Stanley Black & Decker mandatory ‘trades well’; Cytokinetics drags
|
11/8/2019 | CV | New Issue: Cytokinetics prices upsized $120 million seven-year convertibles at 4%, up 27.5%
|
11/7/2019 | CV | Market Commentary: Cytokinetics looks cheap; Stanley Black & Decker tightens talk; China convertibles rise
|
11/7/2019 | CV | Market Commentary: Morning Commentary: Cytokinetics, Stanley Black & Decker on tap; Arbor Realty prices
|
11/6/2019 | CV | Market Commentary: Arbor prices upsized $230 million deal; Cytokinetics, Sierra Oncology offerings on tap
|
11/6/2019 | CV | Cytokinetics to price $100 million convertible notes due 2026 to yield 3.5%-4%, up 27.5%-32.5%
|
11/6/2019 | CV | Cytokinetics to price $100 million convertible notes due 2026
|
10/20/2015 | PP | Cytokinetics could raise $40 million through 7.5% term loan agreement
|
9/4/2015 | PP | Cytokinetics plans to conduct $40 million at-the-market equity program
|
2/25/2014 | PP | Cytokinetics wraps $40.25 million public offering of stock
|
2/20/2014 | PP | Cytokinetics prices $35 million public offering of its stock at $8.00
|
2/19/2014 | PP | Cytokinetics says it plans to price public offering of common shares
|
6/20/2012 | CVPP | Cytokinetics prices $59.98 million public sale of stock and preferreds
|
6/19/2012 | PP | Cytokinetics reports plans for public sales of stock and preferreds
|
11/28/2011 | CVHYPF | Cytokinetics files $100 million shelf for common stock, preferreds
|
7/8/2011 | PP | Cytokinetics plans $20 million at-the-money continuous public offering
|
4/18/2011 | PP | Cytokinetics heralds $20.06 million placement of stock and preferreds
|
10/26/2010 | PP | Cytokinetics extends tenor of $75 million equity financing facility
|
5/19/2009 | PP | New Issue: Cytokinetics arranges $14 million registered direct offering of common-share units
|
5/19/2009 | PP | Market Commentary: Hemispherx arranges offering; Cytokinetics to raise $14 million; Ondine plans equity exchange
|
11/10/2008 | CVHY | Cytokinetics files $100 million shelf
|
10/15/2007 | PP | New Issue: Cytokinetics announces $75 million stock purchase agreement
|
10/15/2007 | PP | Market Commentary: Cytokinetics gets $75 million equity line; White Energy sells A$45 million of convertibles
|
1/3/2007 | PP | New Issue: Cytokinetics sells $33 million of stock to Amgen
|
12/7/2006 | PP | New Issue: Cytokinetics secures $37 million from direct placement of stock
|
11/16/2006 | BT | Cytokinetics to start phase 2 trial of CK-1827452 in heart failure patients before year end
|
10/27/2006 | BT | Cytokinetics kept at outperform by JMP
|
10/27/2006 | BT | Cytokinetics maintained at sector perform by RBC
|
10/26/2006 | BT | Cytokinetics' quarterly net loss up at $14.9 million
|
10/4/2006 | BT | Cytokinetics at market outperform by JMP
|
10/3/2006 | BT | Cytokinetics kept at sector perform by RBC
|
9/14/2006 | BT | RBC maintains Cytokinetics at sector perform
|
9/14/2006 | BT | Cytokinetics reiterated at market outperform by JMP
|
9/13/2006 | BT | Cytokinetics' study determines dosage of cardiac myosin activator
|
8/23/2006 | BT | Cytokinetics starts phase 1 trial to treat heart failure
|
7/28/2006 | BT | JMP reiterates Cytokinetics at outperform
|
7/28/2006 | BT | Cytokinetics reiterated at sector perform by RBC
|
6/30/2006 | BT | JMP reiterates Cytokinetics at market outperform
|
6/29/2006 | BT | Cytokinetics says CK-1827452 may benefit high-risk cardiac patients
|
6/29/2006 | BT | RBC keeps Cytokinetics at sector perform
|
6/29/2006 | BT | Market Commentary: Invitrogen, Geron rise on pact; other stem cell names higher; Keryx up 8%; Nabi up over 2%
|
6/19/2006 | BT | Cytokinetics, GlaxoSmithKline extend research collaboration
|
6/5/2006 | BT | Cytokinetics given sector perform rating by RBC
|
6/5/2006 | BT | Cytokinetics announces positive ispinesib data in four trials
|
5/30/2006 | BT | JMP's Biotechnology Industry Overview
|
4/28/2006 | BT | Cytokinetics stays at market outperform by JMP
|
4/17/2006 | BT | Cytokinetics begins phase 1/2 clinical trial of SB-743921 for lymphoma
|
3/31/2006 | BT | Cytokinetics remains at market outperform by JMP
|
3/30/2006 | BT | Cytokinetics' ispinesib data shows insufficient results, company will not proceed with phase 2 trial
|
3/22/2006 | BT | Cytokinetics obtains $5 million LoC, extends collaboration with Portola Pharm
|
3/3/2006 | BT | JMP reiterates Cytokinetics at market outperform
|
2/16/2006 | BT | JMP reiterates Cytokinetics at market outperform
|
2/1/2006 | BT | JMP reiterates Cytokinetics at market outperform
|
1/20/2006 | BT | Cytokinetics extends $4.5 million line of credit
|
1/18/2006 | BT | JMP says select small-, mid-cap biotech stocks look promising
|
1/18/2006 | PP | Market Commentary: Jefferies stock up 7.8% after $125 million PIPE; Cytokinetics to close $33 million direct offering
|
1/18/2006 | BTPP | New Issue: Cytokinetics gets commitments for $33 million direct placement of stock
|
12/14/2005 | BT | Cytokinetics says heart failure program progressing, work on multiple cell assay may be used in other applications
|
12/13/2005 | BT | Cytokinetics says GlaxoSmithKline selected third development candidate under alliance
|
12/12/2005 | BT | Cytokinetics reiterated by JMP at market outperform
|
12/8/2005 | BT | Cytokinetics' ispinesib shows some anti-tumor activity in phase 2 trial
|
12/7/2005 | BT | Cytokinetics picks CK-1827452 as development candidate for chronic heart failure
|
11/18/2005 | BT | JMP maintains Cytokinetics at market outperform
|
11/17/2005 | BT | Cytokinetics says phase 1b trials show ispinesib combined with chemotherapy effective against solid tumors
|
11/11/2005 | BT | JMP maintains Cytokinetics at market outperform
|
10/31/2005 | PP | Market Commentary: Medicsight raises $7.5 million in stock deal; diving oil, better stocks may fuel PIPE deals, sellsiders say
|
10/28/2005 | BT | Market Commentary: Accentia drops on IPO debut; Point Therapeutics up on deal delay; Myriad Genetics falls
|
10/28/2005 | PP | Market Commentary: Cytokinetics gets $75 million equity line; Telkonet raises $20 million from convertibles
|
10/28/2005 | BTPP | New Issue: Cytokinetics gets $75 million equity line from Kingsbridge Capital
|
10/27/2005 | BT | JMP keeps Cytokinetics at market outperform
|
9/28/2005 | BT | Cytokinetics reiterated by JMP at market outperform
|
9/20/2005 | BT | Cytokinetics maintained by JMP at outperform
|
9/7/2005 | BT | Cytokinetics initiated by JMP at market outperform
|
6/14/2005 | BTCV | Cytokenetics files $100 million shelf
|